Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Non-cash Items (2016 - 2025)

Heron Therapeutics filings provide 13 years of Non-cash Items readings, the most recent being $500000.0 for Q4 2025.

  • On a quarterly basis, Non-cash Items fell 66.67% to $500000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $500000.0, a 66.67% decrease, with the full-year FY2025 number at $500000.0, down 66.67% from a year prior.
  • Non-cash Items hit $500000.0 in Q4 2025 for Heron Therapeutics, down from $1.5 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $12.2 million in Q4 2021 to a low of $500000.0 in Q4 2025.
  • Median Non-cash Items over the past 4 years was $6.4 million (2023), compared with a mean of $6.4 million.
  • Biggest five-year swings in Non-cash Items: crashed 86.83% in 2024 and later crashed 66.67% in 2025.
  • Heron Therapeutics' Non-cash Items stood at $12.2 million in 2021, then decreased by 6.97% to $11.4 million in 2023, then crashed by 86.83% to $1.5 million in 2024, then crashed by 66.67% to $500000.0 in 2025.
  • The last three reported values for Non-cash Items were $500000.0 (Q4 2025), $1.5 million (Q4 2024), and $11.4 million (Q4 2023) per Business Quant data.